Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Thrombomodulin (TM) is a single transmembrane, multidomain glycoprotein receptor primarily expressed by vascular endothelial cells, although it is also found in several other cell types, including neutrophils, synovial lining cells, monocytes, nucleated cells, and osteoblasts. Initially, TM garnered significant attention from researchers because of its ability to regulate coagulation through thrombin activity.
In this study, we aimed to investigate the predictive value of TM in SA-AKI resulting from bacterial infections. The progression of SA-AKI frequently necessitates the administration of vasoactive drugs and Continuous Renal Replacement Therapy (CRRT) to sustain circulation and enhance the internal environment as well as to address the progression of AKI. Consequently, we performed a subgroup analysis to determine whether TM retained its predictive value during the administration of vasoactive drugs and CRRT.
One-way analysis of variance (ANOVA) was applied to variables exhibiting normal distribution and homogeneous variance, whereas rank sum tests were utilized for non-normally distributed variables. Spearman’s correlation analysis was performed to assess relationships. Binary and ordered logistic regression analyses were conducted to evaluate the independent relationships with SA-AKI. A receiver operating characteristic (ROC) curve was employed to determine di-agnostic accuracy.
Thrombomodulin was significantly elevated in patients with AKI compared to that in non-AKI patients, and the odds ratio for thrombomodulin was 1.168 in a multivariable logistic regression analysis. The Area under curve (AUC) value for thrombomodulin in SA-AKI was 0.811. In subgroup analysis, thrombomodulin expression was significantly higher in the vasoactive drug group. The AUC of thrombomodulin with vasopressor use was 0.704. In the group that did not utilize vasoactive drugs, the AUC of thrombomodulin in SA-AKI was 0.813. Thrombomodulin expression was significantly higher in the Continuous Renal Replacement Therapy (CRRT) group. The AUC of Thrombomodulin (TM) when CRRT was used was 0.796. In the group that did not receive CRRT, the AUC of thrombomodulin predicted by SA-AKI was 0.741.
Thrombomodulin may be valuable in independently predicting SA-AKI.
